Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients

European Journal of Internal Medicine

Volumn 21, Issue 4, 2010, Pages 333-337

  Watanabe, Masaaki ^a   Shibuya, Akitaka ^a   Takada, Juichi ^a   Tanaka, Yoshiaki ^a   Okuwaki, Yusuke ^a   Minamino, Tsutomu ^a   Hidaka, Hisashi ^a   Nakazawa, Takahide ^a   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Entecavir; HBV reactivation; Hepatitis B virus (HBV); Immunosuppressive therapy

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; GEMCITABINE; HEPATITIS B SURFACE ANTIGEN; IRINOTECAN; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; RITUXIMAB; VINCRISTINE SULFATE; ANTIVIRUS AGENT; GUANINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; PATIENT MONITORING; PRACTICE GUIDELINE; RELAPSE; REVIEW; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; MIDDLE AGED; PHYSIOLOGY; SECONDARY PREVENTION; TREATMENT OUTCOME; VIRUS ACTIVATION;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SECONDARY PREVENTION; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 77955333837     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.04.010     Document Type: Article

References (37)

1. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
2. D. Ganem, and A.M. Prince Hepatitis B virus infection-natural history and clinical consequences N Engl J Med 350 2004 1118 1129
3. W. Yeo, and P.J. Johnson Diagnosis. Prevention and management of hepatitis B virus reactivation during anticancer therapy Hepatology 43 2006 209 220
4. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
5. G. Lalazar, D. Rund, and D. Shouval Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 136 2007 699 712
6. J.S. Lubel, A.G. Testro, and P.W. Angus Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management Intern Med J 37 2007 705 712
7. T. Umemura, E. Tanaka, K. Kiyosawa, and H. Kumada Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan Clin Infect Dis 47 2008 e52 e56
8. L.H. Katz, A. Fraser, A.G. Gvili, L. Leibovici, and R.T. Kaspa Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis J Viral Hepat 15 2008 89 102
9. R. Loomba, A. Rowley, R. Wesley, T.J. Liang, J.H. Hoofnagle, and F. Pucino Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 2008 519 528
10. Y.H. Li, Y.F. He, W.Q. Jiang, F.H. Wang, X.B. Lin, and L. Zhang Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma Cancer 106 2006 1320 1325
11. C.K. Hui, A. Lie, W.Y. Au, Y.H. Leung, S.Y. Ma, and W.W. Cheung A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation Blood 106 2005 464 469
12. D. Olioso, M. Boaretti, M. Ligozzi, G. Lo Cascio, and R. Fontana Detection and quantification of hepatitis B virus DNA by SYBR green real-time polymerase chain reaction Eur J Clin Microbiol Infect Dis 26 2007 43 50
13. C.K. Chou, L.H. Wang, M.H. Lin, and C.W. Chi Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells Hepatology 16 1992 13 18
14. C.K. Hui, W.W. Cheung, H.Y. Zhang, W.Y. Au, Y.H. Yueng, and A.Y. Leung Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy Gastroenterology 131 2006 59 68
15. A.S. Lok, R.H. Liang, E.K. Chiu, K.L. Wong, T.K. Chan, and D. Todd Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 1991 182 188
16. W. Yeo, B. Zee, S. Zhong, P.K. Chan, W.L. Wong, and W.M. Ho Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy Br J Cancer 90 2004 1306 1311 (Pubitemid 38586252)
17. G.K. Lau, Y.H. Leung, D.Y. Fong, W.Y. Au, Y.L. Kwong, and A. Lie High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation Blood 99 2002 2324 2330
18. W. Yeo, P.K. Chan, S. Zhong, W.M. Ho, J.L. Steinberg, and J.S. Tam Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 2000 299 307
19. W. Yeo, K.C. Lam, B. Zee, P.S. Chan, F.K. Mo, and W.M. Ho Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy Ann Oncol 15 2004 1661 1666 (Pubitemid 39562607)
20. J.W. Jang, J.Y. Choi, S.H. Bae, C.W. Kim, S.K. Yoon, and S.H. Cho Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma J Hepatol 41 2004 427 435
21. H. Nagamatsu, R. Kumashiro, S. Itano, S. Matsugaki, and M. Sata Intervention of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC Hapatol Res 26 2003 293 301
22. W. Yeo, P.K. Chan, P. Hui, W.M. Ho, K.C. Lam, and W.H. Kwan Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study J Med Virol 70 2003 553 561
23. M.S. Dai, P.F. Wu, R.Y. Shyu, and T.Y. Chao Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration Liver Int 24 2004 540 546
24. C.H. Yang, T.S. Wu, and C.T. Chiu Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy Br J Dermatol 157 2007 587 590
25. L.H. Calabrese, N.N. Zein, and D. Vassilopoulos Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 2006 983 989
26. K.N. Lai, J.S. Tam, H.J. Lin, and F.M.M. Lai The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenemia Nephron 54 1990 12 17
27. L.A. Martyak, E. Taqavi, and S. Saab Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis Liver Int 28 2008 28 38
28. Y.F. He, Y.H. Li, F.H. Wang, W.Q. Jiang, R.H. Xu, and X.F. Sun The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma Ann Hematol 87 2008 481 485
29. T.T. Chang, C.L. Lai, R.N. Chien, R. Guan, S.G. Lim, and C.M. Lee Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 2004 1276 1282
30. T.T. Chang, R.G. Gish, R. de Man, A. Gadano, J. Sollano, and Y.C. Chao A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010 (Pubitemid 43357804)
31. A.M. Pelizzari, M. Motta, E. Cariani, P. Turconi, E. Borlenghi, and G. Rossi Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies Hematol J 5 2004 325 328
32. R.J. Colonno, R. Rose, C.J. Baldick, S. Levine, K. Pokornowski, and C.F. Yu Entecavir resistance is rare in nucleoside naïve patients with hepatitis B Hepatology 44 2006 1656 1665
33. G.K. Lau, H.H. Yiu, D.Y. Fong, H.C. Cheng, W.Y. Au, and L.S. Lai Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 2003 1742 1749
34. N. Shinkai, Y. Tanaka, E. Orito, K. Ito, T. Ohno, and N. Hirashima Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection Hepatol Res 36 2006 272 276
35. C.K. Hui, W.W. Cheung, W.Y. Au, A.K. Lie, H.Y. Zhang, and Y.H. Yueng Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy Gut 54 2005 1597 1603
36. J.H. Hoofnagle Reactivation of hepatitis B Hepatology 49 2009 S156 S165
37. S. Kusumoto, Y. Tanaka, M. Mizokami, and R. Ueda Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma Int J Hematol 90 2009 13 23